Clinical Trials Logo

Mestastatic Prostate Cancer clinical trials

View clinical trials related to Mestastatic Prostate Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00770848 Completed - Prostate Cancer Clinical Trials

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Start date: November 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are the following: Phase 1b: To identify a safe dose level of AMG 102, up to 15 mg/kg Q3W, to combine with mitoxantrone and prednisone (MP) Phase 2: To estimate with adequate precision the effect of the addition of AMG 102 to MP, compared with placebo plus MP, as assessed by the hazard ratio (HR) for overall survival (OS) of previously treated subjects with castrate-resistant prostate cancer (CRPC)